公告精选 | 中国中药获私有化要约溢价超三成;携程Q4净营收同比升105%至103亿元

Selected announcements | Chinese Traditional Chinese Medicine received a privatization offer premium of more than 30%; Ctrip's Q4 net revenue increased 105% year-on-year to 10.3 billion yuan

Futu News ·  Feb 22 08:03

A selection of major announcements

1. Chinese traditional Chinese medicine: privatized with a premium of about 34.11% from Sinopharm Group Gongyu and resumed trading on the 22nd

$TRAD CHI MED (00570.HK)$An announcement was issued on the Hong Kong Stock Exchange. Sinopharm Group proposed privatizing Chinese medicines at a cash price of HK$4.6 per share through planned arrangements. Sinopharm's price is a 34.11% premium over the latest closing price of Chinese medicines. The total cost of Sinopharm's privatization proposal is about HK$15.45 billion. China Traditional Chinese Medicine will resume stock trading on February 22.

2. Ctrip Group-S: Net revenue for the fourth quarter was 10.3 billion yuan, up 105% year on year

$TRIP.COM-S (09961.HK)$It was announced that in the fourth quarter of 2023, the company achieved net operating income of RMB 10.338 billion, up 105.48% year on year and down 24.82% month on month; net profit attributable to the group was RMB 1,297 billion, down 36.95% year on year.

3. China People's Insurance Group: The original premium income in January reached 106.030 billion yuan

$PICC GROUP (01339.HK)$According to the announcement, the original premium income received in January through People's Insurance Financial Insurance, People's Insurance Life Insurance and Human Health Insurance was $62,828 billion, $32.04 billion and $11.198 billion respectively, up 2.7%, down 18.5% and 4.5% year-on-year respectively.

4. China Financial Insurance: The original insurance premium income in January was about 62,828 billion yuan, an increase of 2.7% over the previous year

$PICC P&C (02328.HK)$According to the announcement, the company's original insurance premium income from January 1, 2024 to January 31, 2024 reached RMB 62,828 billion, an increase of 2.7% over the previous year.

Earnings Report

$HUAFA PPT SER (00982.HK)$Yingxi: Profit attributable to company owners is expected to increase by no less than 20% year-on-year

$TRIP.COM-S (09961.HK)$: Net revenue for the fourth quarter was 10.3 billion yuan, up 105% year on year

Operational data

$PICC GROUP (01339.HK)$The original premium income reached 106.030 billion yuan in January

$PICC P&C (02328.HK)$: Premium income reached 62,828 billion yuan in January, up 2.7% year-on-year

$KWG GROUP (01813.HK)$: January pre-sale amount was 830 million yuan

$RONSHINECHINA (03301.HK)$Total contract sales in January were approximately RMB 448 million

Important matters for the company

$TRAD CHI MED (00570.HK)$Received a 34.11% privatization premium from Sinopharm Group Gongyu and resumed trading on the 22nd

Issuance of additional shares

$LINGBAO GOLD (03330.HK)$Proposed sale of 32.54 million shares at a discount of approximately 19.76% to raise HK$42 million

Repurchase cancellation

$AIA (01299.HK)$On February 21, 1,112,200 shares were purchased at HK$71.94 million

$YUM CHINA (09987.HK)$On February 20, 99,400 shares were purchased at HK$3.088 million

$SWIRE PACIFIC A (00019.HK)$On February 21, 223,000 shares were repurchased at HK$14.26 million

$COSCO SHIP HOLD (01919.HK)$On February 21, 1.35 million shares were repurchased at HK$11.526 million

$FRONTAGE (01521.HK)$On February 21, 3.8 million shares were repurchased at HK$6.947 million

$ONEWO (02602.HK)$On February 21, 200,000 shares were repurchased at HK$3.726 million

$MEGA GENOMICS (06667.HK)$On February 21, 231,000 shares were repurchased at HK$2.45 million

$BEAUTYFARM MED (02373.HK)$610,000 shares cancelled on February 21


The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment